Empowered Funds LLC Invests $5.76 Million in Teladoc Health, Inc. $TDOC

Empowered Funds LLC acquired a new position in Teladoc Health, Inc. (NYSE:TDOC) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 679,790 shares of the health services provider’s stock, valued at approximately $5,765,000. Empowered Funds LLC owned 0.37% of Teladoc Health at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of TDOC. Public Employees Retirement System of Ohio purchased a new position in Teladoc Health in the second quarter worth about $46,000. Proficio Capital Partners LLC purchased a new stake in shares of Teladoc Health during the 2nd quarter valued at about $106,000. Corient Private Wealth LP bought a new position in shares of Teladoc Health in the 2nd quarter worth approximately $819,000. Freestone Grove Partners LP bought a new position in shares of Teladoc Health in the 2nd quarter worth approximately $7,338,000. Finally, Man Group plc purchased a new position in shares of Teladoc Health in the second quarter worth approximately $6,881,000. Institutional investors own 76.82% of the company’s stock.

Insider Activity

In related news, insider Adam C. Vandervoort sold 7,906 shares of the company’s stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total value of $60,322.78. Following the completion of the transaction, the insider owned 110,261 shares of the company’s stock, valued at approximately $841,291.43. This represents a 6.69% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Fernando M. Rodrigues sold 5,677 shares of the stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total value of $43,315.51. Following the completion of the sale, the insider owned 9,572 shares of the company’s stock, valued at $73,034.36. The trade was a 37.23% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 39,195 shares of company stock worth $299,058 in the last quarter. Corporate insiders own 0.70% of the company’s stock.

Teladoc Health Trading Up 0.2%

Teladoc Health stock opened at $6.51 on Monday. Teladoc Health, Inc. has a 12-month low of $4.40 and a 12-month high of $9.89. The firm has a market capitalization of $1.18 billion, a price-to-earnings ratio of -6.58 and a beta of 2.12. The firm has a 50 day moving average of $7.94 and a 200 day moving average of $6.65.

Teladoc Health (NYSE:TDOC) last issued its quarterly earnings results on Wednesday, July 29th. The health services provider reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.04. The business had revenue of $606.93 million for the quarter, compared to the consensus estimate of $615.44 million. Teladoc Health had a negative net margin of 7.13% and a negative return on equity of 12.15%. The company’s revenue for the quarter was down 4.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.19) earnings per share. Teladoc Health has set its Q3 2026 guidance at -0.300–0.200 EPS and its FY 2026 guidance at -1.000–0.750 EPS. On average, analysts predict that Teladoc Health, Inc. will post -0.89 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on TDOC. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teladoc Health in a report on Wednesday, August 19th. Bank of America lifted their price target on shares of Teladoc Health from $9.00 to $10.50 and gave the stock a “buy” rating in a research note on Tuesday, July 7th. Canaccord Genuity Group cut their price objective on shares of Teladoc Health from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. Finally, Citigroup decreased their target price on Teladoc Health from $11.00 to $7.50 and set a “neutral” rating on the stock in a report on Monday, August 3rd. Five analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Teladoc Health presently has an average rating of “Hold” and a consensus price target of $7.54.

Teladoc Health Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.